Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Carcinoma trials

The registry lists 23 Carcinoma studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 8 are open to participants now and 4 have results posted.

Phase 1 8Phase 2 14No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingNCT07793253Phase 2
• A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingNCT07430202Phase 1
• Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerRecruitingNCT07281768Phase 2
• NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerRecruitingNCT06941857Phase 2
• Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic CancerRecruitingNCT06782932Phase 1/2
• Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingNCT06564623Phase 1
• Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerRecruitingNCT06205836Phase 2
• Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract CancersRecruitingNCT06001658Phase 2
• Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerCompletedNCT05014776Phase 2Results posted
• Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHNCompletedNCT03878979Phase 2Results posted
• A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive TractCompletedNCT01697800Phase 2Results posted
• A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive TractCompletedNCT00894413Phase 2Results posted
• DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)Active, not recruitingNCT06027086Phase 1/2
• Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell CarcinomaTerminatedNCT05103722Not applicable
• Therapy for High-Risk HPV 16-Positive Oropharynx Cancer PatientsWithdrawnNCT04001413Phase 2
• Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)CompletedNCT03299946Phase 1
• Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)WithdrawnNCT02702960Phase 2
• Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell CarcinomaCompletedNCT02575222Phase 1
• Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)TerminatedNCT02485990Phase 1
• Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving ChemoradiationCompletedNCT01958515
• Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal CarcinomaTerminatedNCT00484601Phase 2
• Protein Biomarker in Hepatocellular CarcinomaTerminatedNCT00465842
• MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00427102Phase 1